Central retinal vein occlusion: Difference between revisions
Content deleted Content added
m Dating maintenance tags: {{Pn}} |
m Journal cites, added 1 PMID, completed 1 page range using AWB (11761) |
||
| Line 13: | Line 13: | ||
MeshID = D012170 | |
MeshID = D012170 | |
||
}} |
}} |
||
The [[central retinal vein]] is the venous equivalent of the [[central retinal artery]] and, like that blood vessel, it can suffer from [[Vascular occlusion|occlusion]] ('''central retinal vein occlusion''', also '''CRVO'''<ref>Ophthalmology at a Glance, Jane Olver & Lorraine Cassidy, Blackwell Science 2005.{{ |
The [[central retinal vein]] is the venous equivalent of the [[central retinal artery]] and, like that blood vessel, it can suffer from [[Vascular occlusion|occlusion]] ('''central retinal vein occlusion''', also '''CRVO'''<ref>Ophthalmology at a Glance, Jane Olver & Lorraine Cassidy, Blackwell Science 2005.{{page needed|date=May 2015}}</ref>), similar to that seen in [[ocular ischemic syndrome]]. Since the central retinal artery and vein are the sole source of blood supply and drainage for the [[retina]], such occlusion can lead to severe damage to the retina and blindness, due to [[ischemia]] (restriction in blood supply) and [[macular edema|edema]] (swelling).<ref>{{cite journal |doi=10.1016/S0002-9394(14)70001-7 |pmid=8154523 |title=Incidence of Various Types of Retinal Vein Occlusion and Their Recurrence and Demographic Characteristics |journal=American Journal of Ophthalmology |volume=117 |issue=4 |pages=429–41 |year=1994 |last1=Hayreh |first1=Sohan Singh |last2=Zimmerman |first2=M. Bridget |last3=Podhajsky |first3=Patricia }}</ref> |
||
It can also cause [[glaucoma]]. |
It can also cause [[glaucoma]]. |
||
| Line 22: | Line 22: | ||
Treatment consists of Anti-VEGF drugs like [[Lucentis]] or intravitreal steroid implant (Ozurdex) and Pan-Retinal Laser Photocoagulation usually. Underlying conditions also require treatment. Non-Ischemic CRVO has better visual prognosis than Ischemic CRVO. |
Treatment consists of Anti-VEGF drugs like [[Lucentis]] or intravitreal steroid implant (Ozurdex) and Pan-Retinal Laser Photocoagulation usually. Underlying conditions also require treatment. Non-Ischemic CRVO has better visual prognosis than Ischemic CRVO. |
||
A systematic review studied the effectiveness of the anti-VEGF drugs [[ranibizumab]] and [[pegaptanib|pagatanib sodium]] for patients suffering from non-ischemic CRVO.<ref name="Braithwaite">{{cite journal |doi=10.1002/14651858.CD007325.pub3 |chapter=Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion |title=Cochrane Database of Systematic Reviews |year=2014 |last1=Braithwaite |first1=Tasanee |last2=Nanji |first2=Afshan A |last3=Lindsley |first3=Kristina |last4=Greenberg |first4=Paul B }}</ref> Though there was a limited sample size, participants in both treatment groups showed improved visual acuity over 6 month periods, with no safety concerns.<ref name=Braithwaite/> |
A systematic review studied the effectiveness of the anti-VEGF drugs [[ranibizumab]] and [[pegaptanib|pagatanib sodium]] for patients suffering from non-ischemic CRVO.<ref name="Braithwaite">{{cite journal |doi=10.1002/14651858.CD007325.pub3 |chapter=Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion |title=Cochrane Database of Systematic Reviews |year=2014 |last1=Braithwaite |first1=Tasanee |last2=Nanji |first2=Afshan A |last3=Lindsley |first3=Kristina |last4=Greenberg |first4=Paul B |pmid=20927757 |journal=Cochrane Database Syst Rev |pages=CD007325}}</ref> Though there was a limited sample size, participants in both treatment groups showed improved visual acuity over 6 month periods, with no safety concerns.<ref name=Braithwaite/> |
||
==See also== |
==See also== |
||
Revision as of 17:35, 24 December 2015
| Central retinal vein occlusion | |
|---|---|
| Specialty | Ophthalmology  |
The central retinal vein is the venous equivalent of the central retinal artery and, like that blood vessel, it can suffer from occlusion (central retinal vein occlusion, also CRVO[1]), similar to that seen in ocular ischemic syndrome. Since the central retinal artery and vein are the sole source of blood supply and drainage for the retina, such occlusion can lead to severe damage to the retina and blindness, due to ischemia (restriction in blood supply) and edema (swelling).[2]
It can also cause glaucoma.
Nonischemic CRVO is the milder form of the disease. It may progress to the more severe ischemic type.[3]
Treatment
Treatment consists of Anti-VEGF drugs like Lucentis or intravitreal steroid implant (Ozurdex) and Pan-Retinal Laser Photocoagulation usually. Underlying conditions also require treatment. Non-Ischemic CRVO has better visual prognosis than Ischemic CRVO.
A systematic review studied the effectiveness of the anti-VEGF drugs ranibizumab and pagatanib sodium for patients suffering from non-ischemic CRVO.[4] Though there was a limited sample size, participants in both treatment groups showed improved visual acuity over 6 month periods, with no safety concerns.[4]
See also
References
- ^ Ophthalmology at a Glance, Jane Olver & Lorraine Cassidy, Blackwell Science 2005.[page needed]
- ^ Hayreh, Sohan Singh; Zimmerman, M. Bridget; Podhajsky, Patricia (1994). "Incidence of Various Types of Retinal Vein Occlusion and Their Recurrence and Demographic Characteristics". American Journal of Ophthalmology. 117 (4): 429–41. doi:10.1016/S0002-9394(14)70001-7. PMID 8154523.
- ^ Central Retinal Vein Occlusion at eMedicine
- ^ a b Braithwaite, Tasanee; Nanji, Afshan A; Lindsley, Kristina; Greenberg, Paul B (2014). "Cochrane Database of Systematic Reviews". Cochrane Database Syst Rev: CD007325. doi:10.1002/14651858.CD007325.pub3. PMID 20927757.
{{cite journal}}:|chapter=ignored (help)